Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Propr
26 Febbraio 2008 - 9:29PM
PR Newswire (US)
EAST SETAUKET, N.Y., Feb. 26 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings, Inc. (OTC:LIXT:OB) (BULLETIN BOARD:
LIXT:OB) and its collaborator, the Surgical Neurology Branch (SNB),
National Institute of Neurological Disorders and Stroke (NINDS),
National Institutes of Health (NIH), reported at the 1st
International Conference on Drug Discovery and Development, Dubai,
UAE, February 6, 2008, that its lead compound LB-1, one of a
patent-pending proprietary series of agents, has anti-cancer
activity against medulloblastoma cells growing in culture and in a
mouse model of cancer. Medulloblastoma is the most common brain
tumor of children and is often fatal. Dr. John S. Kovach, the lead
presenter and President and CEO of Lixte, said that the company and
SNB, NINDS are continuing to develop LB-1 and other compounds for
the treatment of human brain cancers. Brain cancers pose a
particular challenge to the development of effective drug
treatments. The brain is protected by a physiological barrier which
prevents the entry of most potentially effective therapeutic
agents. To be effective, drugs must be designed either to pass this
barrier or to be administered directly into the brain. "Lixte is
pursuing both strategies to deliver its lead compounds to brain
cancers," said Dr. Kovach. In other studies done by Lixte
independently of NIH, Dr. Kovach commented, "That LB-1 and other
lead compounds have also been found to have anti-cancer activity
against a broad range of common human cancers growing in cell
culture. The effectiveness of these compounds will now be
determined in mouse models of human cancer, starting with lung and
pancreatic cancer." In addition, Dr. Kovach said that, "Some of
Lixte's compounds have been shown to have anti-fungal activity. We
have found that LB-2.1 and other drugs in a second series of
patent-pending proprietary compounds inhibit the growth of several
types of fungi that cause life-threatening infections in immuno-
compromised patients, such as those with HIV-AIDS or undergoing
bone marrow transplantation. Given this lead, Lixte is initiating
studies to assess the potential value of these compounds for
treatment of serious fungal diseases." About Lixte Biotechnology
Holdings, Inc.: Lixte Biotechnology Holdings, Inc. (Lixte) is a
cancer therapeutics and diagnostics company. Founded as a
biomarker-diagnostics company in 2005, Lixte develops new
chemotherapy drugs targeting molecular abnormalities of common
human cancers. Over the past year, based on the discovery of a new
biomarker for brain cancers by collaborators at NIH, the company is
working with NINDS, NIH to develop more effective treatments for
glioblastoma multiforme (GBM), the most common and most aggressive
type of primary brain cancer in adults and other brain cancers of
adults and children. GBM occurs annually in 20,000 to 25,000 adults
in the United States and in a comparable number of individuals in
Europe. At present, there is no curative treatment known for this
disease. Standard treatment involves surgery, radiation and the use
of one or more chemotherapeutic agents at the time of initial
treatment. At relapse, which occurs in essentially all patients,
the present standard treatment is a drug, Temozolomide, which is
associated with a modest increase in life span measured in weeks.
Thus, there is an urgent need for more effective treatments for
GBM. About the National Institute of Neurological Disorders and
Stroke (NINDS), (NIH): NINDS (http://www.ninds.nih.gov/) is a
component of the National Institutes of Health (NIH), and is the
nation's primary supporter of biomedical research on the brain and
nervous system. The National Institutes of Health (NIH) -- The
Nation's Medical Research Agency -- includes 27 Institutes and
Centers and is a component of the U.S. Department of Health and
Human Services. It is the primary federal agency for conducting and
supporting basic, clinical and translational medical research, and
it investigates the causes, treatments, and cures for both common
and rare diseases. For more information about NIH and its programs,
visit http://www.nih.gov/. Forward-Looking Statements This
announcement contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements
regarding the Company's financial position, business strategy and
other plans and objectives for future operations, and assumptions
and predictions about future product demand, supply, manufacturing,
costs, marketing and pricing factors are all forward-looking
statements. These statements are generally accompanied by words
such as "intend," anticipate," "believe," "estimate,"
"potential(ly)," "continue," "forecast," "predict," "plan," "may,"
"will," "could," "would," "should," "expect" or the negative of
such terms or other comparable terminology. The Company believes
that the assumptions and expectations reflected in such
forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide
assurances that these assumptions and expectations will prove to
have been correct or that the Company will take any action that the
Company may presently be planning. However, these forward-looking
statements are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the condensed
consolidated financial statements and notes thereto included in
Item 1 of the Quarterly Report on Form 10-QSB for the quarter
ending September 30, 2007. For additional information Please see
our Website: http://www.lixte.com/ For Investor Information, please
contact: Frank Benedetto Mirador Consulting, Inc. 561-989-3600
DATASOURCE: Lixte Biotechnology Holdings, Inc. CONTACT: Frank
Benedetto of Mirador Consulting, Inc., +1-561-989-3600, for Lixte
Biotechnology Holdings, Inc. Web site: http://www.lixte.com/
Copyright